FHA
ITCI

Flagship Harbor Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Flagship Harbor Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-170
Closed -$4K – 2196
2020
Q2 		$4K Buy
+170
New +$3.44K ﹤0.01% 1674

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Flagship Harbor Advisors's ITCI Position: Q3 2020 in Review

Flagship Harbor Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2020, closing a stake of 170 shares — an estimated $4K sold.

Flagship Harbor Advisors first reported a position in ITCI in Q2 2020 and held it in 1 quarter. The position peaked at $4K in Q2 2020. 176 funds tracked by Wall St. Rank hold ITCI as of Q3 2020.

  • Flagship Harbor Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2020 after selling out during the quarter.
  • Flagship Harbor Advisors sold 170 Intra-Cellular Therapies Inc. shares in Q3 2020, an estimated $4K.
  • Flagship Harbor Advisors first reported a position in Intra-Cellular Therapies Inc. in Q2 2020 and held it in 1 quarter.
  • Flagship Harbor Advisors's Intra-Cellular Therapies Inc. position peaked at $4K in Q2 2020.
  • 176 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2020.

Based on Flagship Harbor Advisors's 13F filing for Q3 2020, filed 13 Oct 2020.